CryoPort Inc
Suletud
SektorTööstus
15.13 -2.07
Ülevaade
Aktsiahinna muutus
24h
Min
14.61
Max
15.48
Sissetulek | 14M -9.4M |
|---|---|
Müük | 2.3M 48M |
Aktsiakasum | -0.19 |
Kasumimarginaal | -19.733 |
Töötajad | 684 |
EBITDA | 443K -3.2M |
Soovitused | Tugev "osta" hinnang |
|---|---|
12 kuu keskmine prognoos | +0.58% upside |
Järgmine tulemuste avaldamine | 4. aug 2026 |
|---|
Turukapital | 259M 780M |
|---|---|
Eelmine avamishind | 17.2 |
Eelmine sulgemishind | 15.13 |
CryoPort Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
CryoPort Inc Prognoos
Hinnasiht
By TipRanks
0.58% tõus
12 kuu keskmine prognoos
Keskmine 15.57 USD 0.58%
Kõrge 20 USD
Madal 12 USD
Põhineb 7 Wall Streeti analüütiku instrumendi CryoPort Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest CryoPort Inc
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.
